About Crucell
Crucell is a company based in Leiden (Netherlands) founded in 1993 was acquired by Johnson & Johnson in September 2010. Crucell has raised $443 million across 2 funding rounds from investors including Johnson & Johnson and European Union. Crucell operates in a competitive market with competitors including Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Alexion, among others.
- Headquarter Leiden, Netherlands
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$443 M (USD)
in 2 rounds
-
Latest Funding Round
$92.14 K (USD), Grant
Jan 01, 2016
-
Investors
Johnson & Johnson
& 1 more
-
Employee Count
Not available
-
Acquired by
Johnson & Johnson
(Sep 17, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Crucell
Unlock access to complete
Unlock access to complete
Funding Insights of Crucell
Crucell has successfully raised a total of $443M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $92.14 thousand completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Crucell
Crucell has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Johnson & Johnson and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Healthcare solutions are provided by Johnson & Johnson globally.
|
Locked | Locked | Locked |
Investor details for Crucell
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Crucell
Investment portfolio details for Crucell
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Crucell
Detailed financials for Crucell
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Crucell Comparisons
Peer comparison for Crucell
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Crucell
Crucell operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Adaptive Biotechnologies, Generate Biomedicines, HOOKIPA Pharma and Alexion, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Clinical diagnostics and drug discovery for immune diseases are provided.
|
|
| Locked | Locked | Locked |
Developer of novel protein-based therapeutics using machine learning and biological engineering
|
|
| Locked | Locked | Locked |
Developer of immunotherapies for the treatment of infectious diseases and cancer
|
|
| Locked | Locked | Locked |
Therapies for rare and devastating diseases are developed by Alexion.
|
|
| Locked | Locked | Locked |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment.
|
Detailed competitors of Crucell
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Crucell
Complete news archive for Crucell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Crucell
Crucell was founded in 1993 and raised its 1st funding round 16 years after it was founded.
Crucell is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Crucell is a funded company, having raised a total of $443M across 2 funding rounds to date.
Crucell focused on research development, production and marketing of vaccines, proteins and antibodies that prevent andor treat infectious diseases. Crucells core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and aluminum-free hepatitis A vaccine.
Crucell's top competitors include Moderna, argenx and Adaptive Biotechnologies.
Crucell has 2 investors. Key investors include Johnson & Johnson, and European Union.